Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Appili Therapeutics has received the final court approval for its acquisition by Aditxt, Inc., marking a significant milestone in the transaction process. This move will eventually lead to Appili’s delisting from the Toronto Stock Exchange. The transaction is expected to close by the end of 2024, subject to remaining conditions.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.